Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study
Affiliations
- PMID: 32596633
- PMCID: PMC7306190
- DOI: 10.1093/jncics/pkaa018
Abstract
Background: The clinical impact of addressing potential germline alterations from tumor-only next-generation sequencing (NGS) is not well characterized. Current guidelines for cancer genetic testing may miss clinically actionable germline changes, which may have important implications for cancer screening, treatment, and prevention. We examined whether increasing involvement of the clinical genetics service during somatic tumor-only NGS review at Molecular Tumor Board (MTB) increases the detection of germline findings.
Methods: In a retrospective evaluation of patients who underwent tumor-only NGS and were reviewed at MTB, we quantified genetic counseling (GC) referrals as well as germline testing uptake and results across three cohorts: before (C1) and after (C2) the addition of tumor-only NGS review and after (C3) instituting a formal process to coordinate NGS-based genetics referrals to preexisting oncology appointments. All statistical tests were two-sided.
Results: From 2013 to 2017, 907 tumor-only NGS reports were reviewed at MTB (nC1 = 281, nC2 = 493, nC3 = 133); gastrointestinal (22.5%), lung (19.7%), genitourinary (14.8%), and breast (14.1%) were the most common index cancers. GC visits due to MTB increased with each successive cohort (C1 = 1.1%, C2 = 6.9%, C3 = 13.5%; P for trend [P trend] < .001), as did germline testing (C1 = 0.7%, C2 = 3.2%, C3 = 11.3%; P trend < .001). Diagnosis of germline pathogenic variants increased with each successive cohort (C1 = 1.4%, C2 = 2.0%, C3 = 7.5%; P trend = .003) and with germline pathogenic variants found by MTB review (C1 = 0.4%, C2 = 0.4%, C3 = 2.3%; P trend = .12).
Conclusions: Both review of tumor-only NGS by genetics and the institution of a process coordinating GC with oncology appointments increased the discovery of germline pathogenic variants from tumor-only NGS testing. Furthermore, this process identified germline pathogenic variant carriers who would not have otherwise met standard criteria for germline testing.
© The Author(s) 2020. Published by Oxford University Press.
Similar articles
- Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study.Front Oncol. 2019 Jun 26;9:550. doi: 10.3389/fonc.2019.00550. eCollection 2019.PMID: 31297337 Free PMC article.
- Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers.Fam Cancer. 2017 Oct;16(4):545-550. doi: 10.1007/s10689-017-9980-2.PMID: 28315974
- Tumor genome analysis includes germline genome: are we ready for surprises?Int J Cancer. 2015 Apr 1;136(7):1559-67. doi: 10.1002/ijc.29128. Epub 2014 Aug 14.PMID: 25123297 Free PMC article.
- Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.Cancer. 2018 Jul 1;124(13):2704-2713. doi: 10.1002/cncr.31331. Epub 2018 Apr 6.PMID: 29682723 Review.
- Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.J Med Genet. 2018 Dec;55(12):785-793. doi: 10.1136/jmedgenet-2018-105488. Epub 2018 Oct 4.PMID: 30287599 Review.
No hay comentarios:
Publicar un comentario